Moderna, Inc. $MRNA Shares Sold by Contravisory Investment Management Inc.

Contravisory Investment Management Inc. lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 37.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,050 shares of the company’s stock after selling 9,168 shares during the period. Contravisory Investment Management Inc.’s holdings in Moderna were worth $2,898,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. BlackRock Inc. acquired a new position in shares of Moderna during the 2nd quarter worth approximately $2,142,877,000. Theleme Partners LLP acquired a new stake in shares of Moderna during the 2nd quarter worth about $564,272,000. Wellington Management Group LLP increased its position in shares of Moderna by 4.4% during the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after acquiring an additional 103,977 shares during the last quarter. Merck & Co. Inc. purchased a new position in shares of Moderna during the second quarter worth $161,642,545. Finally, Bamco Inc. NY acquired a new position in Moderna in the 2nd quarter valued at about $139,317,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of Moderna stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22. Following the transaction, the president owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 118,882 shares of company stock valued at $16,862,280 in the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investor enthusiasm has strengthened after reports of positive results for Moderna’s mRNA-based cancer vaccine. A planned NIH-backed initiative to accelerate personalized cancer-vaccine development could provide additional funding, visibility and partnership opportunities for the company’s oncology platform. Moderna’s Cancer Vaccine Breakthrough Drives Sharp Stock Rally
• Positive Sentiment: Moderna’s inclusion in the Nasdaq-100 has likely generated index-related buying and increased exposure among institutional investors, contributing to the recent rally. Moderna Stock Has Been on a Winning Streak
• Positive Sentiment: Health Canada is reviewing Moderna’s next-generation mRNA flu vaccine, which the company believes could reduce hospitalizations. Regulatory progress would expand Moderna’s commercial opportunities beyond COVID-19 vaccines. Health Canada Reviewing New mRNA Flu Vaccine
• Neutral Sentiment: Moderna will report third-quarter 2026 results and provide a corporate update on November 6. The report could offer important evidence about revenue trends, cash usage and progress toward its growth targets. Moderna to Report Third Quarter 2026 Financial Results
• Negative Sentiment: After the rapid advance, some investors appear to be reassessing whether Moderna’s oncology and vaccine prospects are already reflected in the share price. Profit-taking and concerns about the company’s continuing losses could increase volatility. Moderna Slides as Investors Reassess Near-Term Catalysts
• Negative Sentiment: Reported insider activity shows company executives selling shares without recorded open-market purchases during the past six months. In addition, several analyst price targets remain well below the current market valuation, highlighting skepticism about Moderna’s earnings outlook. MRNA Stock Gains Over $4B in a Week

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Loop Capital set a $135.00 price objective on Moderna in a report on Wednesday, August 19th. Jefferies Financial Group reiterated a “hold” rating and set a $150.00 price target (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. Rothschild & Co Redburn cut Moderna from a “neutral” rating to a “sell” rating and boosted their price objective for the company from $40.00 to $81.00 in a research note on Thursday, September 3rd. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Moderna in a report on Friday, September 25th. Seven analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $100.60.

Moderna Stock Performance

Shares of MRNA stock traded up $2.51 during trading hours on Tuesday, reaching $216.25. 13,366,030 shares of the company’s stock were exchanged, compared to its average volume of 12,251,396. The company has a market cap of $86.34 billion, a P/E ratio of -27.07 and a beta of 1.09. The company’s 50 day moving average is $143.25 and its two-hundred day moving average is $86.30. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $227.46. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period last year, the firm earned ($2.13) EPS. Equities research analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.